Yonhap Infomax NewsNov 5
IDT Biologika, the European subsidiary of SK Bioscience, is ramping up efforts to secure global CDMO contracts by participating in major industry events and leveraging synergies with its parent company.
#YonhapInfomax #SKBioscience #IDTBiologika #CDMO #VaccineMarket #GlobalOrders #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=89250
SK Bioscience Subsidiary IDT Biologika Pursues Global CDMO Contracts

IDT Biologika, the European subsidiary of SK Bioscience, is ramping up efforts to secure global CDMO contracts by participating in major industry events and leveraging synergies with its parent company.

Yonhap Infomax
Yonhap Infomax NewsNov 3
SK Bioscience narrowed its Q3 operating loss to KRW 19.4 billion as revenue soared 145% year-on-year, driven by vaccine growth and the IDT Biologika acquisition.
#YonhapInfomax #SKBioscience #OperatingLoss #RevenueGrowth #IDTBiologika #VaccineMarket #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=88934
SK Bioscience Narrows Q3 Operating Loss to KRW 19.4 Billion as Revenue Surges 145%

SK Bioscience narrowed its Q3 operating loss to KRW 19.4 billion as revenue soared 145% year-on-year, driven by vaccine growth and the IDT Biologika acquisition.

Yonhap Infomax
Yonhap Infomax NewsFeb 28, 2025
Financial expert advises caution on Tesla and Moderna stocks due to high valuations and potential funding cuts, respectively, amid market uncertainties.
#YonhapInfomax #Tesla #Moderna #StockValuation #VaccineMarket #MarketAnalysis #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=52535
Why Tesla and Moderna Should Be Approached with Caution

Financial expert advises caution on Tesla and Moderna stocks due to high valuations and potential funding cuts, respectively, amid market uncertainties.

Yonhap Infomax